NVCR News and Press, NovoCure Limited From 11/15/21

Median progression-free survival was at least 11.2 months in patients with greater than 9 months of follow-up Partial or complete response was detected in 24% of patients Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Onco...

An oral presentation will feature updated data from the 2-THE-TOP study treating patients with newly diagnosed glioblastoma (GBM) with TTFields plus pembrolizumab and temozolomide Novocure (NASDAQ: NVCR) today announced 31 presentations on Tumor Treating Fields (TTFields...

Novocure (NASDAQ: NVCR) has taken investors on a roller-coaster ride in 2021. Its shares had soared nearly 30% year-to-date at one point, but are now down close to 40%. In this Motley Fool Live video recorded on Nov. 3, 2021 , Motley Fool contributors Keith Speights and Bria...

With the market near all-time highs, conversations around the Thanksgiving table may naturally turn to stocks. No doubt most who've paid attention will marvel at the climb of meme stocks, cryptocurrencies, and companies trading for multiples of their historic valuations. Yet not all com...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q3 2021 Earnings Call Oct 28, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q3 2021 Earnings Call Transcript

Shares of NovoCure (NASDAQ: NVCR) were sinking 15.5% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence . The decline stemmed primarily from the company's disappointing third-quarter update. NovoCure reported net reve...

The following slide deck was published by NovoCure Limited in conjunction with their 2021 Q3 earnings call. For further details see: NovoCure Limited 2021 Q3 - Results - Earnings Call Presentation

NovoCure Limited (NVCR) Q3 2021 Results Conference Call October 28, 2021 08:00 AM ET Company Participants Ingrid Goldberg - VP, Finance and IR Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Pritesh Shah - Chief Commercial Officer Conference Call Participants Cory Kas...

NovoCure (NVCR -6.6%) shares are trading sharply lower in the morning hours after the company lagged expectations with its Q3 2021 financials and forecasted a prolonged timeline for a final data readout from a pivotal study. The maker of Optune Tumor Treating Fields delivery sy...

Novocure (NASDAQ:NVCR) announces that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields ((TTFields)) together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer. Following the completion of en...